Financial Performance
5Y price score: (8)
The price score is a basic measure of the stock's performance against the S&P 500 Index over a five-year period.
A score of 100 indicates that the stock did as well as the S&P 500 Index.
A score below 100 means the stock underperformed the index, while a score above 100 means it outperformed the S&P 500.
10Y return: 127.3%
US$ Per
Share
By default your notes are visible only to you.
163.1
52-week range
428.8
Your model inputs
Your fair value & Margin of safety
To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.
Forecast:
Valuation
Free Cash Flow Yield
(1) %
Dividend Yield TTM
0.9 %
Market cap $
$ 46,227
Price / Earnings TTM
36.5
Price / Book TTM
2.4
PEG TTM
(26)
Earnings growth and return
LTM
5YR
10YR
Total return (price & dividends)
37.8 %
(2.2) %
127.2 %
Free cash flow per share growth
(84.3) %
(91.2) %
36 %
Earnings per share growth
(1.4) %
(61.1) %
16.6 %
Founded: 1,961
Employees: 65,680
Business Summary:
Latest Earnings Call Takeaways
2026 Q2 (Jul 29, 2026)
1) Strategy & Leadership - Humana's leadership expressed satisfaction with year-to-date performance and reaffirmed commitment to achieving a sustainable pretax margin of at least 3% by 2028. - The company is focused on four key drivers: product and experience, clinical excellence, operational efficiency, and growth in CenterWell and Medicaid. - New board members Paul Smith and Fred Crawford bring extensive experience in technology and finance, enhancing the board's expertise.
2) Financial & Segment Results - Humana's 2026 membership growth trajectory is on track, with expectations for continued performance. - The consolidated operating cost ratio improved by 120 basis points YoY, with a full-year reduction expected to be around 150 basis points. - Cost trends for 2026 are projected to be in the high single-digit range (7%-8%), with some favorability noted in inpatient care.
3) Operational Plans & Efficiency - The company is centralizing operations to enhance efficiency, such as consolidating utilization management across 11 markets. - Humana is expanding outsourcing in finance and HR, aiming to improve vendor performance and reduce costs. - The integration of CarePlus operations is expected to drive greater value and scale.
4) Guidance & Outlook - Humana anticipates significant progress in MA margin expansion in 2027, with adjustments to plan mix and benefits. - Approximately 600,000 members may be impacted by planned market exits, but the company aims to recapture a significant portion of that volume. - A virtual investor update is scheduled for December 10, 2026, to discuss progress on commitments and provide insights into membership expectations for 2027.
5) Problems / Headwinds - The company faces uncertainties regarding the Stars program outcomes, with the final data from CMS expected in October. - While Humana is optimistic about its operational progress, it acknowledges the inherent unknowns related to industry thresholds and competitive dynamics.
Bottom line: Humana is executing its strategy effectively, with solid membership growth and operational improvements. The company is on track to meet its long-term margin goals, although it faces challenges related to the Stars program and market dynamics. Investors should remain optimistic about the company's outlook as it prepares for significant developments in 2027.
Annual Reports, Presentations And IR Contacts
Go to the websiteHumana — Financial Overview, Stock Price, Market Cap
Humana is a company. Founded in 1961. As of August 14, 2026, the company's market capitalization is $46227197600 with a current stock price of $384.97.